ArticleEuropean journal of neurology2025
Preliminary Validation of the FCD-Q8 Tool in Functional Cognitive Disorder and Early Alzheimer's Disease: A Biomarker-Verified Case-Control Study.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preliminary Validation of the FCD-Q8 Tool in Functional Cognitive Disorder and Early Alzheimer's Disease: A Biomarker-Verified Case-Control Study.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDifferentiating functional cognitive disorder (FCD) from early Alzheimer's disease (eAD) through clinical interview alone is challenging and may lead to unnecessary testing. We aimed to assess the diagnostic accuracy of the Functional Cognitive Disorder Questionnaire-8 (FCD-Q8) and examine its psychometric properties.
methodsIn this cross-sectional, phase 1 case-control study at a tertiary memory clinic in Seville, Spain, 78 adults with memory complaints were recruited: 44 with biomarker-verified eAD (positive CSF or amyloid PET; GDS 3-4) and 34 with FCD (negative biomarkers and clinical internal inconsistency). A blinded neuropsychologist administered the FCD-Q8. The primary outcome was diagnostic accuracy (area under the ROC curve [AUC], sensitivity, and specificity). Secondary outcomes included internal consistency (Cronbach's α with 95% CI) and item characteristics using two-parameter logistic Item Response Theory (2PL IRT).
resultsParticipants had a mean age of 67.5 years (SD ± 7.1); 59% were female. The FCD-Q8 demonstrated good diagnostic accuracy with an AUC of 0.87 (95% CI 0.78-0.95). At a cut-off ≥ 5, sensitivity was 76.5% and specificity 88.6%. Internal consistency was moderate (α = 0.61; 95% CI 0.47-0.70). 2PL IRT analysis showed that items related to checking behaviours were the most discriminative (difficulty 3.70), while questions on compound statements and premorbid self-appraisal were the least discriminative. Attending the clinical interview alone was the most difficult item (1.47).
conclusionThe FCD-Q8 demonstrated good diagnostic utility to distinguish FCD from eAD in biomarker-verified populations. These findings support progression to a subsequent prospective validation phase, which could further establish its clinical and research applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.